Literature DB >> 27212611

[Predictive and prognostic factors of preeclampsia: Interest of PlGF and sFLT-1].

S Vieillefosse1, J Guibourdenche2, A Atallah3, B Haddad4, T Fournier5, V Tsatsaris6, E Lecarpentier7.   

Abstract

Preeclampsia is characterized by the association of hypertension and a de novo proteinuria in the second half of pregnancy. Currently, obstetrical teams do not have any tool to detect during the first trimester of pregnancy, in low risk population, the patients likely to develop early and severe preeclampsia. On the other hand, there is no diagnostic/prognostic tool in case of strong suspicion of preeclampsia. The Placental Growth Factor (PIGF) and soluble receptor of the Vascular Endothelial Growth Factor (sFlt-1) are respectively two molecules pro- and anti-angiogenic released mainly by the placenta during pregnancy. Numerous experimental and clinical results suggest that an imbalance of pro/anti-angiogenic factors is involved in the pathophysiology of preeclampsia. We selected and analyzed the main studies that have evaluated the predictive, diagnostic and prognostic value of these two biomarkers for preeclampsia.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Angiogenic factors; Biomarkers; Biomarqueurs; Facteurs angiogéniques; Grossesse; PlGF; Placental growth factor; Prediction; Preeclampsia; Prognosis; Prédiction; Prééclampsie; SFlt-1; sFLT-1

Mesh:

Substances:

Year:  2016        PMID: 27212611     DOI: 10.1016/j.jgyn.2016.02.006

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  2 in total

1.  Doppler ultrasound and photoplethysmographic assessment for identifying pregnancy-induced hypertension.

Authors:  Xiurong Sun; Fangming Su; Xuelin Chen; Qihui Peng; Xiaomin Luo; Xinghai Hao
Journal:  Exp Ther Med       Date:  2019-12-31       Impact factor: 2.447

Review 2.  Aspirin for Prevention of Preeclampsia.

Authors:  A Atallah; E Lecarpentier; F Goffinet; M Doret-Dion; P Gaucherand; V Tsatsaris
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.